Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of “palateau”

References

• Qin S, Xv Z, Chen X, Wang S, Lu H, Li J, Guo X, Yang J, Liu C, Wang Y, et al. Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: a Bayesian network meta-regression analysis. Front Oncol. 2023 Feb 22;13:1072634. doi:10.3389/fonc.2023.1072634.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Rebuzzi SE, Roviello G, Catalano M, Brunelli M, Rizzo M. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma. Hum Vaccin Immunother. 2023 Dec 31;19(1):2171672. doi:10.1080/21645515.2023.2171672; Chen YW, Rini BI. Approaches to first-line therapy for metastatic clear cell renal cell carcinoma. Curr Oncol Rep. 2022;24(6):695–702. doi:10.1007/s11912-022-01196-1.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, et al. Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncol. 2023 Jul;18(4):559–7. doi:10.1007/s11523-023-00978-2.
   PubMed Web of Science ®Google Scholar
• Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, et al. Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group? Eur Urol Oncol. 2024 Feb;7(1):102–11. doi:10.1016/j.euo.2023.07.003.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, et al. CLEAR trial investigators. Lenvatinib plus pembrolizumab versus sunitinib in first-line treatment of advanced renal cell carcinoma: final prespecified overall survival analysis of CLEAR, a phase III study. J Clin Oncol. 2024 Apr 10;42(11):1222–8. doi:10.1200/JCO.23.01569.
   PubMedGoogle Scholar
• Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study. Eur Uro. 2023 Nov;84(5):449–54. doi:10.1016/j.eururo.2023.06.006.
   PubMed Web of Science ®Google Scholar
• Burotto M, Powles T, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, et al. Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9 ER trial. J Clin Oncol. 2023 Jul 20;41(21):3767; J Clin Oncol. 2023;41(6_suppl):603–603. doi:10.1200/JCO.2023.41.6_suppl.603.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK, Hammers HJ, Barthélémy P, Plimack ER, Porta C, George S, et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer. 2022 Jun 1;128(11):2085–97. doi:10.1002/cncr.34180.
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 Dec;21(12):1563–73. doi:10.1016/S1470-2045(20)30436-8.
   PubMed Web of Science ®Google Scholar
• Catalano M, Procopio G, Sepe P, Santoni M, Sessa F, Villari D, Nesi G, Roviello G. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: trick or treat? Pharm & Therap. 2023 Sep;249:108499. doi:10.1016/j.pharmthera.2023.108499.
   PubMed Web of Science ®Google Scholar
• Lee D, Gittleman H, Weinstock C, Suzman D, Bloomquist E, Agrawal S, Brave M, Brewer J, Fallah J, Singh H, et al. Food and drug administration-pooled analysis of frontline combination treatment survival benefits by risk groups in metastatic renal cell carcinoma. Eur Urol. 2023 Oct;84(4):373–8. doi:10.1016/j.eururo.2023.05.030.
   PubMed Web of Science ®Google Scholar
• Serzan MT, Xu W, Berg SA. First-line treatment for intermediate and poor risk advanced or metastatic clear cell renal cell carcinoma. Hematol Oncol Clin North Am. 2023 Oct;37(5):951–64. doi:10.1016/j.hoc.2023.04.018.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, et al. COSMIC-313 investigators. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023 May 11;388(19):1767–78. doi:10.1056/NEJMoa2212851.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020 Dec 14;38(6):803–17.e4. doi:10.1016/j.ccell.2020.10.011.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018 Jun;24(6):749–57. doi:10.1038/s41591-018-0053-3.
   PubMed Web of Science ®Google Scholar
• Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, et al. Outcomes associated with first-line anti-PD-1/PD-L1 agents vs. Sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis. Cancers Basel. 2020 Feb 10;12(2):408. doi:10.3390/cancers12020408.
   PubMed Web of Science ®Google Scholar
• Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, et al. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer. 2022 Dec;10(12):e005445. doi:10.1136/jitc-2022-005445.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Jul;23(7):888–98. doi:10.1016/S1470-2045(22)00290-X.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, et al. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer. 2022 Mar;10(3):e004316. doi:10.1136/jitc-2021-004316.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Soulieres D, Melichar B, Vynnychenko I, et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol. 2019;37(15_suppl):4500–4500. doi:10.1200/JCO.2019.37.15_suppl.4500.
   Web of Science ®Google Scholar
• Carretero-González A, Lora D, Martín Sobrino I, Sáez Sanz I, Bourlon MT, Anido Herranz U, Martínez Chanzá N, Castellano D, de Velasco G. The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials. Cancers Basel. 2020 Jul 17;12(7):1945. doi:10.3390/cancers12071945.
   PubMed Web of Science ®Google Scholar
• Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, Motzer R, Hutson TE, Méndez-Vidal MJ, Hong SH, et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2023 Aug 16;13:1223282. doi:10.3389/fonc.2023.1223282.
   PubMed Web of Science ®Google Scholar
• de Coaña YP, Wolodarski M, Poschke I, Yoshimoto Y, Yang Y, Nyström M, Edbäck U, Brage SE, Lundqvist A, Masucci GV, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017 Mar 28;8(13):21539–53. doi:10.18632/oncotarget.15368.
   PubMedGoogle Scholar
• Daly RJ, Scott AM, Klein O, Ernst M. Enhancing therapeutic anti-cancer responses by combining immune checkpoint and tyrosine kinase inhibition. Mol Cancer. 2022 Sep 29;21(1):189. doi:10.1186/s12943-022-01656-z.
   PubMed Web of Science ®Google Scholar
• Zhang N, Tu J, Wang X, Chu Q. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. Immunotherapy. 2019 Apr;11(5):429–41. Epub 2019 Jan 30. doi:10.2217/imt-2018-0110. PMID: 30698054.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023 Mar;24(3):228–38. doi:10.1016/S1470-2045(23)00049-9.
   PubMed Web of Science ®Google Scholar
• Bogani G, Cinquini M, Signorelli D, Pizzutilo EG, Romanò R, Bersanelli M, Raggi D, Alfieri S, Buti S, Bertolini F, et al. A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitoRS in solid tumors: the OTHERS study. Crit Rev Oncol Hematol. 2023 Jul;187:104016. doi:10.1016/j.critrevonc.2023.104016.
   PubMed Web of Science ®Google Scholar
• Kim SH, Jeong KC, Joung JY, Seo HK, Lee KH, Chung J. Prognostic significance of nephrectomy in metastatic renal cell carcinoma treated with systemic cytokine or targeted therapy: a 16-year retrospective analysis. Sci Rep. 2018 Feb 14;8(1):2974. doi:10.1038/s41598-018-20822-2.
   PubMedGoogle Scholar
• Motzer R, George S, Merchan JR, Hutson TE, Song X, Perini RF, Xie R, Bapat U, Puente J. Characterization and management of adverse reactions from the CLEAR study in advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab. Oncologist. 2023 Jun 2;28(6):501–9. doi:10.1093/oncolo/oyac269.
   PubMed Web of Science ®Google Scholar
• Porta C, Eto M, Motzer RJ, De Giorgi U, Buchler T, Basappa NS, Mendez Vidal MJ, Tjulandin S, Park SH, Melichar B, et al. Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study. Ann Oncol. 2022;33(suppl_7):660–80. doi:10.1016/j.annonc.2022.07.1552.
   Web of Science ®Google Scholar
• Fallah J, Gittleman H, Weinstock C, Chang E, Agrawal S, Tang S, Pazdur R, Kluetz PG, Suzman DL, Amiri-Kordestani L. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis. J Natl Cancer Inst. 2024 Mar 14;djae066. doi:10.1093/jnci/djae066.
   PubMedGoogle Scholar
• Soulières D, Rini BI, Plimack ER, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma: subgroup analysis from KEYNOTE-426 by prior nephrectomy. Presented at the International Kidney Cancer Association (IKCS) 2020 virtual annual meeting; 2020 Nov 6–7.
   Google Scholar
• Albiges L, Schmidinger M, Taguieva-Pioger N, Perol D, Grünwald V, Guemas E. CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma. Future Oncol. 2022 Mar;18(8):915–26. doi:10.2217/fon-2021-1006.
   PubMed Web of Science ®Google Scholar
• Marteau F, Harrow B, McCarthy C, Wallace J, Monnette A, Wang Y, Doshi GK. Cabozantinib versus other TKIs after CPI treatment in the real-world management of patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2021;39(6_suppl):293–293. doi:10.1200/JCO.2021.39.6_suppl.293.
   Web of Science ®Google Scholar
• McGregor BA, Lalani AA, Xie W, Steinharter JA, Bakouny Z, Martini DJ, Fleischer JH, Abou-Alaiwi S, Nassar A, Nuzzo PV, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020 Aug;135:203–10. doi:10.1016/j.ejca.2020.05.009.
   PubMed Web of Science ®Google Scholar
• Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020 Mar;84:101966. doi:10.1016/j.ctrv.2020.101966.
   PubMed Web of Science ®Google Scholar
• Amzal B, Fu S, Meng J, Lister J, Karcher H, Bottaro DP. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: a network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLOS ONE. 2017 Sep 8;12(9):e0184423. doi:10.1371/journal.pone.0184423.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Fornarini G, Signori A, Buti S, Procopio G, De Giorgi U, Pignata S, Naglieri E, Maruzzo M, Banna GL, et al. International multicenter real-world registry for patients with metastatic renal cell carcinoma: meet-URO 33 study (REGAL study). J Clin Oncol. 2024;42(4_suppl):485–485. doi:10.21203/rs.3.rs-3419200/v1.
   Google Scholar
• Shah NJ, Sura SD, Shinde R, Shi J, Singhal PK, Robert NJ, Vogelzang NJ, Perini RF, Motzer RJ. Real-world treatment patterns and clinical outcomes for metastatic renal cell carcinoma in the current treatment era. Eur Urol Open Sci. 2023 Feb 6;49:110–18. doi:10.1016/j.euros.2022.12.015.
   PubMedGoogle Scholar
• Study design of the the CARE-1 RLT trial. https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-kidney-cancer/145009-asco-2023-doublet-and-triplet-therapy-for-metastatic-rcc-the-case-for-doublet-therapy.html.
   Google Scholar